RxDoctor Payments Data

Shalendra Varma, MD

Cardiovascular Disease · Fishersville, VANPI 1912991746

Payments from drug & device makers

$2,767in general payments, 2019–2025

Across 50 payments — averaging $55.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Boehringer Ingelheim$220
  • Edwards Lifesciences$181
  • Amgen$165
  • Abiomed$105
  • Astellas Pharma US Inc$90
  • plus $652 from 14 others

What the payments were for

  • Travel & lodging$1,10840%
  • Food & beverage$1,55656%
  • Education$1044%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,767 in reported general payments places this provider in the 60th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$292,469
Medicare patients
2,232
Services billed
6,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$137,270
BrilintaTicagrelor50$29,841
EntrestoSacubitril/Valsartan38$28,740
XareltoRivaroxaban18$27,460
JardianceEmpagliflozin22$13,330
Metoprolol Succinate389$4,445
Atorvastatin Calcium220$2,202
ClopidogrelClopidogrel Bisulfate192$1,731
Amlodipine Besylate332$1,565
Diltiazem 24hr Er (Cd)Diltiazem Hcl49$1,273
Ranolazine ErRanolazine14$1,179
Carvedilol158$1,123
Losartan Potassium96$1,043
Potassium Chloride26$879
Rosuvastatin Calcium43$820

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$75$137,270131 claims
AstraZenecaBrilinta$31$29,84150 claims
NovartisEntresto$82$28,74038 claims
Johnson & JohnsonXarelto$80$27,46018 claims
Boehringer IngelheimJardiance$220$13,33022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Fishersville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →